The 57% uORR in pancreatic cancer and the accelerated registration-enabling trial plans are strong positive catalysts for ERAS. However, this is an early-stage, single-arm Phase 1 dataset with limited patients (N=7 at RDE). Monitor for additional confirmatory data, particularly the initiation of the planned Phase 3 trials and the H1 2027 data readouts. The prior historical win rate on this ticker is high (78% at T+20), supporting a bullish directional call.
Price Chart
Executive Summary
Erasca reported encouraging preliminary Phase 1 data for ERAS-0015, its pan-RAS molecular glue, showing a 57% unconfirmed overall response rate (uORR) at 8 weeks in 2L+ KRAS G12X pancreatic cancer at the 32 mg QD recommended dose. The company outlined accelerated development plans including a potentially registration-enabling trial in lung cancer in H1 2027 and a Phase 3 pancreatic cancer trial in 2027, which for an early-stage biotech is a significant positive catalyst.
Key Facts
- 57% uORR8wk in 2L+ KRAS G12X pancreatic cancer at RDE of 32 mg QD (N=7).
- Median relative dose intensity of 100% at both 24 mg QD and 32 mg QD.
- No DLTs observed; therapy generally well-tolerated with no discontinuations due to TRAEs.
- First dose escalation combination cohort of ERAS-0015 (16 mg) with panitumumab cleared without DLTs.
- Plan to initiate potentially registration-enabling trial in 2L+ NSCLC in H1 2027.
- Plan to initiate Phase 3 pivotal trial in 1L pancreatic cancer in 2027.
- Additional ERAS-0015 monotherapy and combination data expected in H1 2027.
Financial Impact
Early-stage biotech with no disclosed revenue; the Phase 1 update and registration-enabling plans represent a transformative pipeline catalyst for a company with a $5.8B market cap.
Risk Factors
- Early Phase 1 data with small sample size (N=7 at RDE); response rates may change with more patients.
- Unconfirmed responses may not all convert to confirmed partial responses.
- Potential IP litigation with Revolution Medicines over ERAS-0015 patent infringement allegations.
- Registration-enabling trial plans subject to FDA feedback and may be delayed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3326444 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 24, 2026 5w ago | 8-K | $17.60 $15.55 | ▼ −11.65% | ▼ −12.96% | $14.94 (−15.09%) |
Aug 17, 2026 6w ago | 144 | $18.28 $16.16 | ▼ −11.60% | ▼ −10.07% | $14.94 (−18.24%) |
Aug 13, 2026 7w ago | Institutional Cluster | $17.86 $15.88 | ▼ −11.09% | ▼ −9.34% | $14.94 (−16.32%) |
Aug 12, 2026 7w ago | 3 | $17.86 $15.88 | ▼ −11.09% | ▼ −9.34% | $14.94 (−16.32%) |
Aug 11, 2026 7w ago | Press Release | $18.58 $16.03 | ▼ −13.72% | ▼ −11.83% | $14.94 (−19.56%) |
Jul 22, 2026 10w ago | Press Release | $19.51 $18.07 | ▲ +7.38% | ▲ +10.28% | $14.94 (+23.40%) |
Jul 14, 2026 11w ago | 8-K | $21.26 $18.58 | ▼ −12.61% | ▼ −14.95% | $14.94 (−29.70%) |
Jul 14, 2026 11w ago | 424B5 | $21.26 $18.58 | ▼ −12.61% | ▼ −14.95% | $14.94 (−29.70%) |
Jul 14, 2026 11w ago | Press Release | $19.50 $18.31 | ▲ +6.10% | ▲ +8.59% | $14.94 (+23.36%) |
Jul 13, 2026 11w ago | Press Release | $19.50 $18.31 | ▼ −6.10% | ▼ −8.59% | $14.94 (−23.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access